209 related articles for article (PubMed ID: 28571972)
41. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y; Yaguchi T; Kubo A; Iwata T; Morii K; Kato D; Ohta S; Satomi R; Yamamoto Y; Oyamada Y; Ouchi K; Takahashi S; Ishioka C; Matoba R; Suematsu M; Kawakami Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793868
[TBL] [Abstract][Full Text] [Related]
42. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
43. Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Vasilevich NI; Parkhill EQ; Glushkov AI; Zilbershtein TM; Mayboroda EI; Boze MA; Cole AG; Henderson I; Zautke NA; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3050-3. PubMed ID: 19394219
[TBL] [Abstract][Full Text] [Related]
44. An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 - 2013).
Powell DA
Expert Opin Ther Pat; 2014 Feb; 24(2):155-75. PubMed ID: 24251719
[TBL] [Abstract][Full Text] [Related]
45. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery.
Brown JM; Rudel LL
Curr Opin Lipidol; 2010 Jun; 21(3):192-7. PubMed ID: 20216310
[TBL] [Abstract][Full Text] [Related]
46. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Uto Y; Ogata T; Kiyotsuka Y; Miyazawa Y; Ueno Y; Kurata H; Deguchi T; Yamada M; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Konishi M; Kurikawa N; Kono K; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4159-66. PubMed ID: 19541482
[TBL] [Abstract][Full Text] [Related]
47. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
49. Sequential Dynamics of Stearoyl-CoA Desaturase-1(SCD1)/Ligand Binding and Unbinding Mechanism: A Computational Study.
Petroff AB; Weir RL; Yates CR; Ng JD; Baudry J
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680068
[TBL] [Abstract][Full Text] [Related]
50. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
Dobrzyn P; Dobrzyn A
Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
[TBL] [Abstract][Full Text] [Related]
51. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design.
Dong X; Zhan W; Zhao M; Che J; Dai X; Wu Y; Xu L; Zhou Y; Zhao Y; Tian T; Cheng G; Jin Z; Li J; Shao Y; He Q; Yang B; Weng Q; Hu Y
J Med Chem; 2019 Aug; 62(15):7264-7288. PubMed ID: 31298542
[TBL] [Abstract][Full Text] [Related]
52. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease.
Zhang Z; Dales NA; Winther MD
J Med Chem; 2014 Jun; 57(12):5039-56. PubMed ID: 24295027
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
54. Discovery of Cytochrome P450 4F11 Activated Inhibitors of Stearoyl Coenzyme A Desaturase.
Winterton SE; Capota E; Wang X; Chen H; Mallipeddi PL; Williams NS; Posner BA; Nijhawan D; Ready JM
J Med Chem; 2018 Jun; 61(12):5199-5221. PubMed ID: 29869888
[TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Mizojiri R; Nii N; Asano M; Sasaki M; Satoh Y; Yamamoto Y; Sumi H; Maezaki H
Bioorg Med Chem; 2019 Jun; 27(12):2521-2530. PubMed ID: 30879862
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Xia G; You X; Liu L; Liu H; Wang J; Shi Y; Li P; Xiong B; Liu X; Shen J
Eur J Med Chem; 2013 Apr; 62():1-10. PubMed ID: 23353742
[TBL] [Abstract][Full Text] [Related]
57. Radiosynthesis and Preliminary Evaluation of [
Li KP; Gleba JJ; Parent EE; Knight JA; Copland JA; Cai H
Mol Pharm; 2023 Aug; 20(8):4129-4137. PubMed ID: 37409698
[TBL] [Abstract][Full Text] [Related]
58. Tetrahydrobenzothiophene carboxamides: Beyond the kinase domain and into the fatty acid realm.
Llona-Minguez S; Fayezi S; Alihemmati A; Juárez-Jiménez J; Piedrafita FJ; Helleday T
Bioorg Med Chem Lett; 2017 Sep; 27(18):4462-4466. PubMed ID: 28807439
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
[TBL] [Abstract][Full Text] [Related]
60. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]